InMed Pharmaceuticals Inc.
INM
$2.96
$0.24378.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.83M | 4.96M | 4.60M | 5.63M | 5.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.83M | 4.96M | 4.60M | 5.63M | 5.49M |
| Cost of Revenue | 3.12M | 3.39M | 3.50M | 3.42M | 3.38M |
| Gross Profit | 1.71M | 1.57M | 1.10M | 2.21M | 2.11M |
| SG&A Expenses | 5.56M | 5.37M | 5.25M | 5.45M | 5.48M |
| Depreciation & Amortization | 217.40K | 219.40K | 219.60K | 218.30K | 214.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.60M | 12.22M | 12.73M | 12.27M | 12.48M |
| Operating Income | -7.77M | -7.26M | -8.13M | -6.64M | -6.99M |
| Income Before Tax | -7.91M | -6.81M | -7.67M | -6.07M | -6.35M |
| Income Tax Expenses | 7.10K | 7.10K | 7.10K | 1.80K | 3.30K |
| Earnings from Continuing Operations | -7.91 | -6.82 | -7.68 | -6.08 | -6.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.91M | -6.82M | -7.68M | -6.08M | -6.35M |
| EBIT | -7.77M | -7.26M | -8.13M | -6.64M | -6.99M |
| EBITDA | -7.55M | -7.04M | -7.91M | -6.42M | -6.78M |
| EPS Basic | -13.97 | -14.04 | -26.57 | -24.57 | -32.99 |
| Normalized Basic EPS | -8.72 | -8.76 | -16.60 | -15.35 | -20.61 |
| EPS Diluted | -13.97 | -14.04 | -26.57 | -24.57 | -32.99 |
| Normalized Diluted EPS | -8.72 | -8.76 | -16.60 | -15.35 | -20.61 |
| Average Basic Shares Outstanding | 2.29M | 1.98M | 1.53M | 1.21M | 897.80K |
| Average Diluted Shares Outstanding | 2.29M | 1.98M | 1.53M | 1.21M | 897.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |